We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Very Large Database of Lipids (VLDL) (VLDL)

This study is ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier:
First Posted: October 3, 2012
Last Update Posted: August 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
VAP Diagnostics Lab
Information provided by (Responsible Party):
Johns Hopkins University
October 1, 2012
October 3, 2012
August 21, 2017
April 2006
April 2016   (Final data collection date for primary outcome measure)
all-cause mortality [ Time Frame: up to 9 years from time of baseline lipid profile ]
Not Provided
Complete list of historical versions of study NCT01698489 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
The Very Large Database of Lipids (VLDL)
The Very Large Database of Lipids (VLDL): A Clinical Laboratory Big Data Project

Closer examination of granular lipid data in a large population offers numerous opportunities to generate new knowledge, ranging from studies examining concordance between commonly used lipid parameters to phenotypic characterization of rare or extreme disorders of lipid metabolism, opening possibilities to better personalize future treatment of abnormal blood lipids.


The Very Large Database of Lipids (VLDL) includes adults and children who were clinically referred for a Vertical Auto Profile (VAP).


The VAP test (VAP Diagnostis Lab, Birmingham, Alabama, USA) directly measures cholesterol concentrations of low density lipoprotein, very low density lipoprotein, intermediate density lipoprotein, high density lipoprotein, their subfractions, and lipoprotein(a). Triglycerides in the database are directly measured using the Abbott ARCHITECT C‐8000 system (Abbott Park, Illinois, USA). Lipid distributions in the database closely match those from the population-representative National Health and Nutrition Examination Survey (NHANES).


This database was investigator-initiated. Only de-identified data reach the investigational site. The first data harvest was in 2011 and the second in 2016. The master database is housed at The Johns Hopkins Hospital in Baltimore, Maryland, and maintained by Drs. Jones and Martin. Only electronic data, and not biospecimens, are sent to Hopkins. The academic investigators have unrestricted access to study data, take responsibility for the accuracy of analyses, and have authority over manuscript preparation and submission.


The variables currently in the VLDL database are testing date, age, sex, fasting/nonfasting, and components of the VAP test. From these primary variables, many additional variables were derived for inclusion in the master database (e.g., non-HDL-C, Friedewald LDL-C, TC/HDL-C, etc.). Other analytes measured by validated assays in subsets of the VLDL database include apoB, apoA1, hsCRP, homocysteine, uric acid, insulin, hemoglobin A1c, 25-hydroxy vitamin D, cystatin C, Liproprotein-associated Phosphatase (Lp-PLA2), Thyroid Stimulating Hormone (TSH), free T3 and T4, pro- Brain Natiuretic Peptide (BNP), direct bilirubin, Creatine Phosphokinase (CPK), creatinine and other components of the comprehensive metabolic panel, magnesium, and phosphate.


In the current database, each record represents a unique patient. The 1st available VAP test for each patient is included. To meet the needs of a variety of research questions, we are prospectively planning to organize harvest 2 data into 3-year interval datasets (i.e., VLDL 2006-2008, 2009-2011, VLDL 2012-2014, etc), a summation dataset (first VAP test for each patient), serial lab dataset (patients who have had repeated testing), and ancillary datasets (subsets of patients with coexisting data on other measures such as apolipoproteins, vitamin D, hs-C-Reactive Protein (CRP), TSH/T4, etc).


Individual VLDL studies are based on a priori hypotheses or aims with statistical analysis plans (SAPs) peer-reviewed prior to execution. In the expandable "Detailed Description" section below, the VLDL investigators will periodically register individual studies and update their status on clinicaltrials.gov.


  • VLDL-1A: Friedewald Estimated versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications (abstract presented; manuscript published; citation provided below)
  • VLDL-1B: Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile. (manuscript published; citation provided below)
  • VLDL-1C: Low-Density Lipoprotein Cholesterol Estimation at Very Low Levels and Clinical Implications (abstract presented; manuscript under review)
  • VLDL-1D: Fasting vs non-fasting impact on low-density lipoprotein-cholesterol accuracy (abstract accepted for presentation; manuscript in preparation)
  • VLDL-2A: Non-High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention (abstract presented; manuscript published; citation provided below)
  • VLDL-2B: Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol (abstract presented; manuscript published; citation provided below)
  • VLDL-3: Deficient Serum 25-Hydroxy Vitamin D is Associated with an Atherogenic Lipid Profile (abstract presented; manuscript published; citation provided below)
  • VLDL-4: Relationship of the Triglyceride to High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio to the Remainder of the Lipid Profile (abstract presented; manuscript published; citation provided below)
  • VLDL-5: Ratio of Dense to Buoyant LDL Subclass and LDL Density Phenotype (abstract presented; manuscript published; citation provided below)
  • VLDL-6: Characterization of Fredrickson-Levy Dyslipidemia Classes without Chylomicrons (IIa, IIb, III,IV) (abstract presented; manuscript in preparation)
  • VLDL-7: Characterization of Fredrickson-Levy Dyslipidemia Classes with Chylomicrons (I,V) (abstract presented; manuscript in preparation)
  • VLDL-8: Continuum of Non-Chylomicron Dyslipidemia Phenotype not Classifiable by Fredrickson-Levy Criteria (abstract presented; manuscript in preparation)
  • VLDL-9: Lipid Phenotypes at the Extremes of High-Density Lipoprotein Cholesterol (abstract presented; manuscript published; citation provided below)
  • VLDL-10A: Atherogenic Lipid Levels in 662,711 Elderly Persons: The Very Large Database of Lipids 10A (abstract presented; manuscript in preparation)
  • VLDL-10B: Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Mid-Life (abstract presented; manuscript published; citation provided below)
  • VLDL-11: Exploration of individuals with American Heart Association (AHA) ideal total cholesterol (<200 mg/dL) (statistical analysis plan in development)
  • VLDL-12: Extremely low LDL-C, non-HDL-C phenotype (statistical analysis plan in development)
  • VLDL-13: Thyroid function vs. lipids (abstract presented; manuscript in preparation)
  • VLDL-14: Seasonal variation in lipids and biomarkers (abstract presented; manuscript in preparation)
  • VLDL-15: Lipids, hsCRP, Lp(a), LpPLA2: phenotypes, lipid oxidation, inflammation (statistical analysis plan in development)
  • VLDL-16: Secular trends in MetSyn lipid criteria, RLP-C (statistical analysis plan in development)
  • VLDL-17: Screening for familial hypercholesterolemia (abstract presented; manuscript published; citation provided below)
  • VLDL-18: RLP-C definitions (statistical analysis plan in development)
  • VLDL-19: Lipoprotein(a) in familial hypercholesterolemia (statistical analysis plan in development)
  • VLDL-20: Lipoprotein subfractions and uric acid (abstract in preparation)
  • VLDL-21: Lipoprotein subfractions and homocysteine (abstract in preparation)
  • VLDL-22: Lipoprotein(a), HDL-C, and TG (abstract in preparation)
  • VLDL-23: Dual LDL-C and hs-CRP target attainment (statistical analysis plan in development)
Observational Model: Other
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Patients clinically referred for VAP density gradient ultracentrifugation.
Lipid Disorders and Lipid Measurement
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
April 2020
April 2016   (Final data collection date for primary outcome measure)
Patients with age and lipid data are included in the master database. Eligibility criteria are specific to each individual study.
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Johns Hopkins University
Johns Hopkins University
VAP Diagnostics Lab
Study Director: Steven R Jones, MD Johns Hopkins University
Principal Investigator: Seth S Martin, MD, MHS Johns Hopkins University
Johns Hopkins University
August 2017